Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.41 -0.48 (-1.91%)
Streaming Delayed Price Updated: 3:17 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
From Pacira BioSciences
Via GlobeNewswire
In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
Top 5 Health Care Stocks That May Explode In July
Via Benzinga
NASDAQ:PCRX: good value for what you're paying.
For those who appreciate value investing, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is a compelling option with its solid fundamentals. 
Via Chartmill
NASDAQ:PCRX, an undervalued stock with good fundamentals.
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued. 
Via Chartmill
Analyst Ratings For Pacira BioSciences
Via Benzinga
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Via Benzinga
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
Via Benzinga
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
When you look at PACIRA BIOSCIENCES INC (NASDAQ:PCRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Navigating 4 Analyst Ratings For Pacira BioSciences
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Preview: Pacira BioSciences's Earnings
Via Benzinga
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
From Pacira BioSciences
Via GlobeNewswire
PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024
PCRX stock results show that Pacira BioSciences met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
Via AB Newswire
Topics Death
Exposures Death
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
From Pacira BioSciences
Via GlobeNewswire
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.